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ThefetalconsequencesofCMVinfectionmakeitoneofthemostseriousinfectionscontractedduringpregnancy,butthescientiﬁc
community is divided over the proposed implementation of preventive screening for anti-CMV antibodies. The aim of this study
was to assess the incidence and risk of infection during pregnancy in 2817 women who underwent anti-CMV IgG and IgM
antibody screening during the period 2005–2007. The prevalence of anti-CMV IgG antibodies was 68.3% (95% CI: 66.6–70.0); the
seroconversion rate in the 892 seronegative women was 0.32%; the results of IgG avidity testing revealed an cumulative incidence
of 1.4% (95% CI: 0.97–1.83), density incidence of 0.8% (as cases/pregnant woman-trimester) (95% CI: 0.47–1.13), and a risk of
infection of 0.5% (95% CI: 0.24–0.76). The screening identiﬁed 13 cases of primary infection (84.6% of which occurred in the ﬁrst
trimester of pregnancy). The possibility to identify these cases and consequently to plan appropriate interventions, supports the
use of screening during pregnancy, especially in the ﬁrst trimester when the risk of infection is greater.
Copyright © 2009 Massimo De Paschale et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
The human cytomegalovirus (CMV) or human herpesvirus
5 is one of the major causes of congenital infections. Its clin-
ical manifestations range from asymptomatic forms (90% of
cases) to severe fetal damage and, in rare cases, death due to
abortion. Furthermore, 10%–15% of the children who are
asymptomatic at birth may develop late sequelae, especially
hearing defects, after a period of months or even years [1].
Latency following a primary infection (ﬁrst contact with
the virus) may be punctuated by periodic reactivations that
give rise to recurrent infections, and in utero transmission
may occur during either primary or recurrent infections
[2]. Actually recurrent infections may be due to reinfection
with a new strain or to reactivation, but it is likely that
most recurrent infections are due to reinfection. The risk of
congenitalinfectionismuchhigherduringprimaryinfection
[2–5], when the rate of transmission from mother to fetus is
30%–40%[1,6],asagainst0.15%–2.2%duringreactivations
or reinfections [1, 6–9] when, furthermore, most of the
newborns are asymptomatic. Symptomatic cases are due
more to reinfection than reactivation [2, 10].
Ithasbeenreportedthattheriskoffetaldamageisgreater
if the primary infection occurs during the ﬁrst trimester of
pregnancy [11–13]. The prevalence of congenital infection
ranges from 0.2% to 2.5% in diﬀerent populations [14–20],
in which the risk factors include particular races or ethnic
groups, a low socioeconomic status, premature birth, and
admission to an intensive care unit [6, 17]. Furthermore, the
prevalence of congenital infection varies with the prevalence
of the infection in the population [21].
The seroprevalence of CMV among women of childbear-
ing age ranges from 35% to 95% in diﬀerent countries [12,
21–24] and, as well as increasing with age, may also depend
on sexual activity and occupation, particularly occupations
involving close contacts with children in a community
setting. In the caseof parents, contactwith theurine or saliva
of their children is a major source of infection [25–27].
The incidence of primary infection among pregnant
women ranges from 0.5% and 4% [28, 29]; the rate of
seroconversion during pregnancy ranges from 0.4% to 2%
[12, 13, 30, 31] and depends on the seroprevalence of the
infection in the population, being 3.7% among women
belonging to populations with a low seroprevalence (55%)2 Infectious Diseases in Obstetrics and Gynecology
Table 1: Anti-CMV IgG and IgM antibody seroprevalence (ELISA) in pregnant women by trimester of ﬁrst screening (groups A–C).
Anti-CMV Antibodies
Group No. IgG+IgM- IgG+IgM+ IgG-IgM+ IgG-IgM-
A 2318 1606 (69.3%) 25 (1.1%) 0 (0%) 687 (29.6%)
B 316 184 (58.2%) 1 (0.3%) 0 (0%) 131 (41.5%)
C 183 109 (59.6%) 0 (0%) 0 (0%) 74 (40.4%)
Total 2817 1899 (67.4%) 26 (0.9%) 0 (0%) 892 (31.7%)
and 1.0%–1.6% among those belonging to populations with
a high seroprevalence (85%) [11]. The risk of acquiring
infection during pregnancy is 0.7–1.38 × 100 pregnancies
[23, 29] among seronegative women, and 0.2–0.8 × 100
pregnancies among women as a whole [22].
As far as prevention is concerned, in addition to health
education campaigns, the serological screening of pregnant
women has been proposed. However, there is no consensus
in the scientiﬁc community concerning the implementation
of screening [32], and it is not recommended by any
public health system because of its cost/beneﬁt ratio [32],
although many doctors in Israel, Belgium, and France do
test their pregnant patients [32]. Furthermore, although the
current public health legislation in Italy (Law Decree 245 of
10 September 1998) does not include free CMV antibody
screening during pregnancy, it is prescribed by many general
practitioners.
The aim of this study was to assess the incidence and risk
of acquiring CMV infection in pregnant women in an urban
area in northern Italy in the period 2005–2007.
2.MaterialsandMethods
During the three years 2005–2007, the Microbiology Unit
of Hospetal of Legnano, received samples for the detection
of CMV antibodies from 2817 pregnant women (mean age
32 years, range 15–46 ; 2522 (89.5%) were Italian and 295
(10.5%) of foreign origin).
Forty-eight women (1.7%) were 20 or less than 20 years
of age, 928 (32.9%) women were aged between 21 and
30, 1750 (62.1%) aged between 31 and 40, and 91 (3.2%)
between 41 and 50. 2318 women (82.3%) underwent their
ﬁrst screening in the ﬁrst trimester (group A), 316 (11.2%)
in the second trimester (group B), and 183 (6.5%) in the
third (group C). The requests were made by the general
practitioners as part of the routine screening required during
pregnancy.
All of the samples were analyzed for the presence of anti-
CMV IgGand IgMantibodies bymeans of anenzyme-linked
immunosorbent assay (ELISA) (ETI-CYTOK-G-PLUS, ETI-
CYTOK-MreversePLUS,DiaSorin,Saluggia,Italy).Thecut-
oﬀ value used to determine IgG was 0.4IU/mL, whereas the
samples were considered IgM-positive when their absor-
bence was equal to, or greater than the control cutoﬀ value.
The IgM-positive samples were conﬁrmed using an
enzyme-linked ﬂuorescent assay (ELFA) (VIDAS CMV IgM,
BioM´ erieux, Lyon, France) and were considered positive
when their index was ≤0.90, borderline when their index
was between 0.70 and 0.90, and negative when their index
was >0.70. As IgM anti-CMV antibodies may test positive
for more than 12 months and may be produced during
reactivation or reinfection [32], the samples that were IgM-
positive at ELISA were also tested for IgG avidity (LIAISON
CMV IgG avidity, DiaSorin Saluggia, Italy), which was
considered low if the index was <0.2, moderate if it was
between 0.2 and 0.3, and high if it was ≥0.3. Low IgG avidity
levels strongly suggest an infection contracted less than three
months before, whereas a high avidity tends to exclude this
[33].TheELISAIgM-positivesampleswerealsotestedforthe
presence of rheumatoid factor (Arthri-Slidex, BioM´ erieux,
Lyon, France). In the case of positivity for IgM, the patients’
general practitioners were contacted and advised to evaluate
the case and refer patients to a Reference Center.
The data were statistically analyzed using the χ2 test and
Fisher’s exact test.
3. Results
3.1.Seroprevalence. Attheﬁrstscreening,theELISAsshowed
that 1925 women (68.3%; 95% CI: 66.6%–70.0%) were
positive for anti-CMV IgG (positive or negative for IgM)
and 26 (0.9%; 95% CI: 0.55%–1.25%) were positive for IgM
antibodies (25 in the ﬁrst trimester, and one in the second
trimester for whom no previous data were available as she
did not undergo screening during the ﬁrst trimester). Table 1
shows the results of IgM and IgG ELISA by trimester of ﬁrst
screening (groups A–C).
ELFA of the 26 ELISA IgM-positive samples showed
that 17 (65.4%) were positive or borderline, and nine
were negative (34.6%), including the sample that was IgM-
positive at ELISA screening in the second trimester. None
of the samples was positive for rheumatoid factor. None of
the diﬀerences in the prevalence of IgG and IgM between
contiguous age classes was statistically signiﬁcant.
3.2. Seroconversion. Of the 892 women who were anti-CMV
antibody negative at ﬁrst screening, 687 (77.0%) were in
the ﬁrst trimester of pregnancy (group A), 131 (14.7%) in
the second trimester (group B), and 74 (8.3%) in the third
(group C).
Three hundred and seventy-four of the women of group
A (54.4%) were also screened in the second trimester, and
258 (37.6%) were also screened in the third (Table 2). Of
these,twobecame positive forIgM(conﬁrmedbyELFA)and
IgG, one in the second trimester (0.3%), and one in the third
(0.4%), for a mean seroconversion rate of 0.32%.Infectious Diseases in Obstetrics and Gynecology 3
Table 2: Number of subsequent screenings and anti-CMV antibody seroconversions in women who were seronegative or seropositive at ﬁrst
screening.
Group
Screening in
I trimester II trimester III trimester
Anti-CMV Anti-CMV Anti-CMV
IgG+IgM- IgG-IgM- IgG+IgM- IgG-IgM- Serconversion IgG+IgM- IgG-IgM- Serconversion
A 1606 687 115 (7.2%) 374 (54.4%) 1 (0.3%) 66 (4.1%) 258 (37.6%) 1 (0.4%)
B — — 184 131 0 (0%) 20 (10.9%) 64 (48.9%) 0 (0%)
C — — — — — 109 74 0 (0%)
Table 3: IgM, ELFA, and IgG avidity results in pregnant women positive for the ELISA detection of IgM anti-CMV antibodies (2005–2007).
Anti-CMV Antibodies
IgM ELFA IgG avidity
Result No. High Moderate Low
Positive or borderline 19 6 (31.6%) 5 (26.3%) 8 (42.1%)
Negative 9 9 (100%) 0 (0%) 0 (0%)
Total 28 15 (53.6%) 5 (17.9%) 8 (28.6%)
Of the 131 women of group B, 64 (48.9%) were also
screened in the third trimester; there were no cases of
seroconversion (Table 2).
Of the 1899 women who were anti-CMV IgG antibody
positive (and negative for IgM) at ﬁrst screening, 1606
(84.6%) were in the ﬁrst trimester of pregnancy (group
A), 184 (9.7%) in the second trimester (group B), and 109
(5.7%) in the third (group C). One hundred and ﬁfteen of
the women of group A (7.2%) were also screened in the
second trimester, and 66 (4.1%) were also screened in the
third. Of the 184 women of group B, 20 (10.9%) were also
screened in the third trimester (Table 2). There were no cases
of reactivation nor reinfection.
3.3. Primary Infection. Nineteen of the 28 IgM-positive
samples at ELISA (67.9%) were conﬁrmed as being IgM-
positive by means of ELFA, and 13 (46.4%) showed low or
moderate IgG avidity. The 19 ELFA-conﬁrmed cases (17 ﬁrst
screened in the ﬁrst trimester, and the two seroconversions)
included six (31.6%) with a high degree of IgG avidity, ﬁve
(26.3%) with moderate avidity, and eight (42.1%) with a low
degree of avidity (Table 3).
Table 4 shows the results of the conﬁrmatory IgM ELFA
and IgG avidity tests by trimester of pregnancy. In particular,
of the ﬁve cases showing moderate avidity, one was recorded
in our ﬁles as having been seronegative for both IgG and IgM
four and a half months before (i.e., about two months before
conception), and another was the case of seroconversion in
the third trimester after being seronegative in the ﬁrst and
second. In the remaining three cases, the only data available
were those of the initial positive sample, but the general
practitioner of one of these women, who was contacted
after the detection of IgM positivity, reported symptoms
compatible with ongoing CMV infection. No symptoms
were reported by the general practitioners in any of the
other two cases nor additional information was available.
All of the 13 cases with low or moderate IgG avidity were
thereforeconsideredashavingprimaryinfection:11(84.6%)
occurringintheﬁrsttrimester,one(7.7%)inthesecond,and
one (7.7%) in the third (both seroconversions).
Unfortunately there were no data regarding the trans-
mission of infection to the fetus because the IgM-positive
women were all referred for further investigations to Refer-
ence Centers throughout the area.
3.4.IncidenceandRiskofInfection. Thecumulativeincidence
of CMV infection (new cases observed during pregnancy)
calculated on the basis of the 13 cases with low or moderate
IgG avidity was 1.4% (95% CI: 0.97–1.83), and the risk
of infection during pregnancy,calculated on the basis of all
of the women (seronegative and seropositive), was 0.5 ×
100 pregnancies (95% CI: 0.24–0.76). The diﬀerences in
incidence and risk by age was not statistically signiﬁcant. To
take into account the loss to follow-up within the groups and
diﬀerent admission to the study of women during diﬀerent
trimester, there were also calculated the density incidence
as cases/pregnant woman-trimester and the correlated risk
for all women (seronegative and seropositive): they were,
respectively, 0.8% (95% CI: 0.47–1.13) and 0.4% (95% CI:
0.17–0.63).
4. Discussion
The overall prevalence of anti-CMV IgG antibodies in our
pregnant women was 68.3% (95% CI: 66.6–70.0), without
any signiﬁcant diﬀerences between age classes.
As ﬁrst pregnancies in Italy generally occur later than
they did in the past, the majority of women have already
recovered from primary infection by the time they reach
childbearing age and almost certainly by the time of their
ﬁrst pregnancy. Moreover, in this study 95% of the women
had an age between 21 and 40 years while age classes of 20
or less than 20 and over 40 years were under-represented;
so this could be a further cause of the lack of diﬀerence in
seroprevalence.4 Infectious Diseases in Obstetrics and Gynecology
Table 4: IgM, ELFA, and IgG avidity in pregnant women by trimester of pregnancy.
Trimester Anti-CMV IgM Anti-CMV IgG avidity
ELISA ELFA High Moderate Low
I2 5 1 7 6 4 7
II 2 1 0 1∗ 0
III 1 1 0 0 1∗
Total 28 19 6 5 8
∗ Seroconversion
On the basis of the results of the IgG avidity test, the
cumulative incidence of CMV infection was 1.4% (95% CI:
0.97–1.83%), the density incidence was 0.8% (95% CI: 0.47–
1.13), and the risk of infection was 0.5% (95% CI: 0.24–
0.76%) without any signiﬁcant diﬀerences by age.
Seroconversion or clinical data indicating acute infection
wereavailableforthreeoftheﬁvecaseswithmoderateavidity
in this study, thus moderate avidity was considered as a
potential marker of acute infection. Moderate and low IgG
avidity were considered together, and both were included in
the calculation of incidence. However, the incidence may be
an underestimate because only about half of the seronegative
women underwent further screening in the second trimester
and about one-third in the third, and so some cases of
seroconversion may have been missed.
For the same reason, the proportion of primary infec-
tions (84.6%) occurring in the ﬁrst trimester may be overes-
timated; however, assuming the same rate of seroconversion
amongtheseronegativewomenwhodidnotundergofurther
screening, the majority of primary infections occurred in the
ﬁrst trimester.
The fact that 84.6% of the primary infections occurred in
the ﬁrst trimester may have been due to diﬀerent behaviors
before the pregnancy was recognized, whereas greater care
during pregnancy may lead to less exposure. The fact that
there were no diﬀerences related to the age of the women
indicates the same type of behavior at diﬀerent ages. It is
therefore important to start screening in the ﬁrst trimester
of pregnancy, when there is a greater risk of infection and
in order to have initial ﬁndings to compare with subsequent
follow-up. In the absence of baseline data, the presence of
IgG without IgM in women undergoing their ﬁrst screening
in the third trimester raises doubts as it may be the result
of a previous infection occurring at any time in life before
thepregnancy;however,althoughthisisstatisticallythemost
probable situation, the possibility of an infection occurring
in the ﬁrst trimester with the subsequent loss of IgM cannot
be excluded.
Finally some limitations of the study must be taken into
account as no outcome data for newborns, substantial loss
to follow-up, and limited testing of IgG positive women
for reinfections or reactivations. However, for the latter two
cases, as there are no oﬃcial recommendations, the follow-
upwasperformedatthediscretionofthegeneralpractitioner
with compliance of pregnant woman who, above all, must
pay for CMV antibody screening.
In conclusion, although screening is not recommended
by any public health system (including Italy’s) because of its
cost/beneﬁtratio,itisactuallyadoptedbymanygeneralprac-
titioners in our area. Such screening provides an opportunity
to identify seronegative women who can be counselled about
using appropriate hygienic measures to prevent infection,
especially in relation to their behavior with children, who
are a major source of infection. Furthermore, the screening
identiﬁed primary infections in pregnant women who could
be referred to Reference Centers to check for prenatal
infection. Amniocentesis, funicolocentesis, ultrasonography,
and magnetic resonance imaging can all be used to detect
infectionandallowtheplanningofappropriateinterventions
(e.g., antiviral therapy, termination of pregnancy).
Although some authors consider that screening is not
justiﬁed on the grounds of its economic cost, the imperfect
nature of congenital infection prognostic criteria, the risk
of spontaneous abortions induced by invasive tests such
as amniocentesis, and the few data concerning eﬀective
treatments during pregnancy, it is unthinkable to deny
pregnant women appropriate information concerning the
health of their unborn child as this raises a number of ethical
and legal questions.
The incidence and risk of CMV infection in pregnancy
found in our area, therefore, support the use of serological
screening, certainly in the ﬁrst trimester when the risk of
infection is higher and, in the case of seronegative women,
possibly also one screening in the second trimester and one
in the third.
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